Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model.
Vaccines are promising for the control of toxoplasmosis. Here, we evaluated the immunogenicity of 17 peptides derived from SAG1 surface protein of Toxoplasma gondii in CH3 mice. Only 8 of 16 peptides induced specific antibodies. After a lethal challenge, only the vaccination with 4 of 17 peptides that were from the carboxy terminal end of the protein conferred significant survival. Our work shows that vaccination with peptides from the carboxy-terminal positions of SAG1 major surface protein of Toxoplasma protects mice against a lethal challenge.
Laboratorio de Inmunologia, Facultad de Medicina, Universidad del Rosario, Bogota, Colombia.
Heber
H
Siachoque
Fanny
F
Guzman
Javier
J
Burgos
Manuel Elkin
ME
Patarroyo
Jorge Enrique
JE
Gomez Marin
D000595:Amino Acid Sequence; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D000953:Antigens, Protozoan / Q000737:chemistry / Q000276:immunology*; D000954:Antigens, Surface / Q000737:chemistry / Q000276:immunology; D007117:Immunization, Secondary; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry / Q000276:immunology; D015800:Protozoan Proteins / Q000737:chemistry / Q000276:immunology*; D016052:Protozoan Vaccines / Q000276:immunology; D014122:Toxoplasma / Q000276:immunology*; D014124:Toxoplasmosis, Animal / Q000517:prevention & control*
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000954:Antigens, Surface; D010455:Peptides; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; C047168:SAG1 antigen, Toxoplasma